Wire · opportunities
PharmaEssentia's Besremi receives FDA approval for ET
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 1 September 2026 · Fusion42 review
The FDA has approved PharmaEssentia’s Besremi (ropeginterferon alfa-2b-njft) for treating adults with essential thrombocythaemia (ET), marking the first FDA-approved ET treatment in nearly 30 years. The approval, based on the Phase III SURPASS ET trial, expands Besremi’s indications in the US, complementing its prior authorization for polycythaemia vera (PV).
This Wire brief sits within Fusion42's coverage of Biotech, and 8 sources have reported it between 31 Aug 2026 and 1 Sep 2026.
◆ ◆ The Wire takeaway
You now face new competition or partnership opportunities in blood cancer treatment with Besremi’s FDA nod expanding access beyond polycythaemia vera to essential thrombocythaemia. Reassess drug positioning and market entry plans for myeloproliferative neoplasms accordingly.
◆ Coverage
8 sources · first reported 31 Aug 2026 · latest 1 Sep 2026
◆ Related on Wire
◆ Topics